Analysts see an average 32.6% upside for Auna S.A., though the outlook hinges on execution across its vertically integrated Latin American healthcare platform. JPMorgan maintained a Hold rating and lowered its price target to $5 from $6 on May 26, while the broader analyst set compiled by S&P Global still shows a Buy consensus and an average target of $6.99 with seven analysts covering the company. Fitch affirmed Auna's B+ rating on May 22, noting material leverage levels. The company operates hospitals and clinics in Mexico, Peru, and Colombia, along with prepaid healthcare, dental and vision insurance, oncology plans, and medicines.
Auna S.A.Analyst consensus shows 32.6% upside but JPMorgan lowered price target and Fitch noted material leverage, creating mixed signals.